Wall Street Journal Announces ReShape^® FDA Approval

FDA OKs Nonsurgical Device for Treating Obesity

ReShape system uses two connected silicone balloons placed in patient’s stomach through mouth with endoscope

The Food and Drug Administration approved a nonsurgical device for treating obesity that includes two connected silicone balloons filled with salt water that are placed in a patient’s stomach. The device, called the ReShape Intragastric Dual Balloon System, fills space in the stomach of obese adults to help with weight loss.

The device, called the ReShape Integrated Dual Balloon System, fills space in the stomach of obese adults to help with weight loss. The FDA said it is limited to patients who have failed to lose weight through other methods and who have one or more obesity-related conditions, such as high blood pressure, high cholesterol and diabetes.

The device’s maker, ReShape Medical® of San Clemente, Calif., described the device as a reversible option designed to promote long-term healthier habits.

To read the full story on WSJ.com, click here.

ReShape^® is Now FDA Approved in the United States

A Review of Unmet Needs in Obesity Management

Clinical Data from European Commercial Use